Professional Documents
Culture Documents
Id Assignment
Id Assignment
Abstract
The introduction of vaccines against Human Papillomaviruses (HPV) marked a major milestone
in the history of preventive oncology. With more than a decade of implementation, these
vaccines have proven efficacious and cost-effective in preventing HPV-related cancers and
anogenital warts. Mathematical models have predicted that the implementation of HPV
vaccination along with screening programs will avert more than 12 million cervical cancer cases
by 2069. This predicted impact remains challenged by poor access to these vaccines in low-
income countries which unfortunately bare the highest burden of HPV-related diseases. The
world health organization (WHO) global strategy to eliminate cervical cancer through
vaccination and screening programs has emphasized the need to improve access to HPV
vaccines. With such optimistic strategies, HPV vaccines will continue to bring down the
incidence of HPV-associated cancers and anogenital warts over the next decades on a global
scale.
Introduction
Globally, the human papillomavirus (HPV) continues to devastate the health of women
accounting for more than 300,000 cervical cancer-related deaths in 20201. HPV accounts for
4.5% of all infection-related cancers2-5 and plays a major role in the etiology of cervical cancer,
the fourth most common cancer among women globally4. HPV oncogenic viruses have also been
linked to oropharyngeal, vulvovaginal, penile, and anal cancers6. Thus, HPV-related morbidity
spreads across all populations, though the most devastating effects have been seen among
women suffering from cervical cancer. Vaccines against HPV have been in use for over a decade
lesions, and warts7. These vaccines are cost-effective and the world health organization (WHO)
Globally, HPV infections stand at 11-12% with the highest-burden in sub-Saharan Africa at
24%9,10. At least 90% of sexually active men and women get infected with HPV once in their life
time5. HPV is an icosahedral, non-enveloped, double-stranded DNA virus that belongs to the
Papillomaviridae family with more than 125 subtypes forty of whom have been identified in
anogenital lesions11. The human papillomaviruses (HPVs) have been classified as low-risk HPVs
(LR-HPVs) that cause anogenital and cutaneous warts like HPV 6,11, and high-risk HPVs (HR-
HPVs) like HPV 16,18 which cause oropharyngeal, cervical, anal, vulvar, vaginal, and penile
cancers 11. Among people living with HIV, its natural history is accelerated making HPV-
associated malignancies and other anogenital lesions more prevalent in this special group11.
Worldwide, there are three vaccines that have been licensed by the U.S. Food and Drug
Administration (FDA) for use in prevention of HPV-related cancers and anogenital warts. All are
approved for the prevention of HPV 16,18 is given at 0,1 and 6 months among girls and women
9-25 years of age. The quadrivalent vaccine, Gardasil, from Merck approved for the prevention
of HPV 6,11,16, 18 is given at 0,2 and 6 months to girls and women of 9-26 years of age. The
nonavalent, Gardasil-9, in addition to HPV 6,11,16 and 18, has efficacy against other strains
including HPV 31,33,45,52,58. It is approved for use among females 16-25 years11.
HPV vaccination started in the early 2000s in developed countries12 and studies demonstrated its
cost-effectiveness13. Though many women from high- and middle-income countries have been
vaccinated, women from low-income countries where the burden of HPV-related disease is
highest have limited access to these vaccines14. Data continues to emerge from countries that
have implemented HPV vaccination showing a reduction in anogenital infections and cervical
intraepithelial neoplasia15. In Australia, the impact of HPV vaccination was visible more than 10
years ago with a 60% reduction in the incidence of anogenital warts16. It is estimated that HPV
vaccination programs coupled with early screening could reduce mortality from cervical cancer
by two-thirds in developing countries17. In 2017, WHO recommended that all member states
implement HPV vaccination for girls 9-14 years of age but even then, the global HPV vaccine
coverage remains unsatisfactory14,18. In 2019, the global HPV vaccine coverage for final dose
was still low at only 15%19. By mid-year 2020, at least half of the WHO member states had
implemented HPV vaccination programs with most introductions in the Americas and Europe19.
In 2018, Uganda and Rwanda were the only developing countries with high completion rates of
84% and 74% respectively14. However, in 2019, there were more introductions than ever in low-
and middle-income countries where access had previously been a problem19. Mathematical
models have shown that wide HPV vaccination and cervical cancer screening coverage if
implemented from 2020 onwards have the potential to avert more than 12 million deaths by
206920. On the background of such models and other data, WHO adopted a strategy to eliminate
cervical cancer by 2030 with targets of 90% of girls fully vaccinated with the HPV vaccine by
age 15, 70% of women screened with high-performance tests by age 35, and repeated by 45
years of age and 90% of women with cervical disease identified and receive treatment8. But of
course, these targets could be challenged by limited access to vaccines in the low- and middle-
income countries and their impact may remain a privilege of wealthy countries14. However, the
new strategy of WHO emphasizes the need and efforts to improve access to HPV vaccines in
low-income countries8. With such optimistic targets and global efforts, the impact of HPV
vaccine will not only be a privilege of wealthy countries but will be demonstrated across all
Conclusion
HPV vaccines have been in use for over a decade and indeed they have been found efficacious
and cost effective in reducing HPV-related morbidity. The WHO and the scientific research
community has demonstrated faith in the gains these vaccines can bring to the health of
populations globally. With expanded access to HPV vaccines, a balanced impact in the reduction
of HPV-related cancers and anogenital warts will surely be very evident across the globe over